GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (LTS:0I3Q) » Definitions » Cyclically Adjusted PB Ratio

Corcept Therapeutics (LTS:0I3Q) Cyclically Adjusted PB Ratio : 24.21 (As of Jun. 02, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Corcept Therapeutics Cyclically Adjusted PB Ratio?

As of today (2025-06-02), Corcept Therapeutics's current share price is $77.2155. Corcept Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $3.19. Corcept Therapeutics's Cyclically Adjusted PB Ratio for today is 24.21.

The historical rank and industry rank for Corcept Therapeutics's Cyclically Adjusted PB Ratio or its related term are showing as below:

LTS:0I3Q' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 8.14   Med: 15.39   Max: 61.22
Current: 22.17

During the past years, Corcept Therapeutics's highest Cyclically Adjusted PB Ratio was 61.22. The lowest was 8.14. And the median was 15.39.

LTS:0I3Q's Cyclically Adjusted PB Ratio is ranked worse than
96.73% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs LTS:0I3Q: 22.17

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Corcept Therapeutics's adjusted book value per share data for the three months ended in Mar. 2025 was $6.447. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.19 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Corcept Therapeutics Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Corcept Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corcept Therapeutics Cyclically Adjusted PB Ratio Chart

Corcept Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.51 11.84 9.49 12.36 15.31

Corcept Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.98 10.97 14.80 15.31 32.70

Competitive Comparison of Corcept Therapeutics's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Corcept Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Corcept Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Corcept Therapeutics's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=77.2155/3.19
=24.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corcept Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Corcept Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=6.447/134.9266*134.9266
=6.447

Current CPI (Mar. 2025) = 134.9266.

Corcept Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.106 100.684 0.142
201509 0.124 100.392 0.167
201512 0.169 99.792 0.229
201603 0.184 100.470 0.247
201606 0.232 101.688 0.308
201609 0.282 101.861 0.374
201612 0.367 101.863 0.486
201703 0.438 102.862 0.575
201706 0.583 103.349 0.761
201709 0.756 104.136 0.980
201712 1.665 104.011 2.160
201803 1.868 105.290 2.394
201806 2.098 106.317 2.663
201809 2.248 106.507 2.848
201812 2.398 105.998 3.052
201903 2.486 107.251 3.128
201906 2.623 108.070 3.275
201909 2.930 108.329 3.649
201912 3.240 108.420 4.032
202003 3.573 108.902 4.427
202006 3.926 108.767 4.870
202009 4.215 109.815 5.179
202012 4.483 109.897 5.504
202103 4.385 111.754 5.294
202106 4.513 114.631 5.312
202109 4.685 115.734 5.462
202112 3.547 117.630 4.069
202203 3.839 121.301 4.270
202206 4.147 125.017 4.476
202209 4.397 125.227 4.738
202212 4.654 125.222 5.015
202303 4.896 127.348 5.187
202306 4.113 128.729 4.311
202309 4.482 129.860 4.657
202312 4.900 129.419 5.109
202403 5.267 131.776 5.393
202406 5.711 132.554 5.813
202409 6.101 133.029 6.188
202412 6.465 133.157 6.551
202503 6.447 134.927 6.447

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Corcept Therapeutics  (LTS:0I3Q) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Corcept Therapeutics Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics Business Description

Traded in Other Exchanges
Address
101 Redwood Shores Parkway, Redwood City, CA, USA, 94065
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.

Corcept Therapeutics Headlines

No Headlines